Abstract
The early detection of tumor, recurrence of tumor and the ability to correlate tumor response to therapy are important components of the Nuclear Medicine Service at Memorial Sloan Kettering Cancer Center. The benefit of a nuclear medicine procedure is derived from its potential to image functional processes in tissues and to monitor the response of these physiologic functions to pathologic processes and treatments. The majority of nuclear medicine methods in common practice today are qualitative in nature. The evolution of imaging equipment, the integrated computerized processing systems, and the specifically designed radiopharmaceutical compounds have the promise however, of greatly extending the assessment of physiologic processes. The potential now exists for an accurate estimate of quantitative biochemical processes both for normal and neoplastic tissues. Specific examples of radionuclides and radiopharmaceuticals applied to oncology are detailed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
R. Doll and R. Peto, The causes of cancer, J. Natl. Cancer Inst. 66:1191(1981).
Trends in cancer mortality in industrial countries, edited by Davis D.I., and Hoel D., New York: NY Academy of Sciences, 1990, p.ix–xi.
E. Silverberg and J.A. Lubera, Cancer statistics, 1988. Cancer 38:5(1988).
J.F. Fraumeni, R.N. Hoover, S.S. Devesa, and L.J. Kinlen Epidemiology of cancer, in: “Cancer: Principles and Practice of Oncology,” V.T. DeVita, S. Hellman, and S.A. Rosenberg, ed., J.B. Lippincott, Philadelphia (1989).
A.M. Scott and S.M. Larson, Tumor diagnosis and therapy, in: “Radiologic Clinics of North America,” E. Coleman, ed., W.B. Saunders, Inc., New York (1993).
R.A. Weinberg, Tumor suppressor genes, Science 254:1138 (1991).
D. Wynford-Thomas, Oncogenes and anti-oncogenes: the mole-cular basis for tumor behavior, J. Path., 165:187 (1991).
H. Macapinlac, A. Scott, F. Daghighian, S. Yeh, J. Ginos, J. Tjuvajev, J. Zhang, R. Finn, S. Larson, and R. Blasberg, I-131-Iododeoxyuridine (IUdR) imaging of brain tumor proliferative activity, Clin. Nucl. Med. 18:263(1993).
J. Ginos, R. Finn, P. Kothari, R. Blasberg, and S. Larson, An investigation into the preparation and chemical stability of radiohalogenated deoxyuridines (UdR) for SPECT and PET imaging. Third International Symposium on Radiohalogens, Banff Centre for Conferences, Banff, Alberta, Canada 9/20–23, 1992 (Abstract).
H. Macapinlac, J. Finlay, C. Caluser, S. Yeh, A. Scott, R. DeLaPaz, K. Lindsley, R. Finn, S. Larson, and H. Abdel Dayem, Comparison of Tl-201 SPECT and F- 18 FDG PET imaging with MRI (Gd-DTPA) in the evaluation of recurrent supratentorial and infratentorial tumors, J. Nucl. Med. 33:867(1992).
H. Macapinlac, A. Scott, C. Caluser, S. Yeh, J. Finlay, R. DeLaPaz, K. Lindsley, S. Al-Mohannadi, H. Abdel-Dayem, and S. Larson, Utility of Tl-201 SPECT and F-18 FDG PET as an adjunct to CT and MR Imaging in the evaluation of metastatic brain tumors, Radiology 185:P233(1992).
C.A. Pellizari, G.T.Y. Chen, et al., Accurate three dimensional registration of CT, PET and/or MRI inages of the brain, J. Comput. Assist. Tomogr. 14:20(1989).
H. Macapinlac, J. Zhang, H. Kalaigian, S. Yeh, A. Scott, C. Caluser, R. DeLaPaz, J. Finlay, R. Blasberg, G. DiResta, R. Finn, K. Lindsley, M. Bernstein, and S. Larson, Registration of Tl-201 SPECT and PET images in patients with primary brain tumors, Radiology 185:P234(1992).
I. Pastan, M.M. Gottesmann, Multiple-drug resistance in human cancer, N. Eng. J. Med. 316:1388(1987).
V. Ling, P-glycoprotein and resistance to anti-cancer drugs, in: “Accomplishments in Cancer Research 1991,” J.G. Fortner and J.E. Rhoads, eds., J.B. Lippincott Co., Philadelphia(1991).
J.M. Fort, and W.N. Hait. Pharmacology of drugs that alter multidrug resistance in cancer, Pharmacol. Rev. 42:155(1990).
T. Tsuruo, Mechanisms of multidrug resistance and im-plications for therapy, Jpn. J. Cancer Res. 79:285(1988).
T. Tsuruo, H. Iida, S. Tsukagoshi, et al., Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil, Cancer Res. 41:1967 (1981).
L.M. Slater, P. Sweet, J. Stupecky, et al., Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro, J. Clin. Invest. 77:1405(1986).
M. Naito, T. Oh-Hara, A. Yamazaki, et al., Reversal of multidrug resistance by an immunosuppressive agent FK-506, Cancer Chemother. Pharmacol. 29:195(1992).
D.E. Merkel, S.A.W. Fuqua, A.K. Tandon, S.M. Hill, A.U. Buzdar, and W.L. McGuire, Electrophoretic analysis of 248 clinical breast cancer specimens for P-glyco-protein overexpression or gene amplification, J. Clin. Oncol. 7:1129(1989).
P. Verelle, F. Meissonmier, Y. Fonck, et al., Clinical relevance of immunohistochemical detection of multidrug-resistance in breast carcinoma, J. Natl. Cancer Inst. 83:111(1991).
B.M. Mehta, E. Rosa, J.D. Fissekis, J.R. Bading, J.L. Biedler, and S.M. Larson, In-vivo identification of tumor multidrug resistance with 3H-colchicine, J. Nucl. Med. 33:1373(1992).
H. Hamada and T. Tsuruo, Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies, Proc. Natl. Acad. Sci. U.S.A. 83:7785(1986).
H.J. Broxterman, C.M. Kuiper, G.J. Schuurhuis, T. Tsuruo, H.M.N. Pinedo, and J. Kankelma, Increase of daunorubicin and vincristine accumulation in multidrug resistant human ovarian carcinoma cells by a monoclonal antibody reacting with P-glycoprotein, Biochem. Pharmacol. 37:2389(1989).
T. Tsuruo, H. Hamada, S. Sato, et al., Inhibition of multidrug-resistant human tumor growth in athymic mice by anti-P-glycoprotein monoclonal antibodies. Jpn. J. Cancer Res. 80:627(1989).
J.W. Pearson, W.E. Fogler, K. Volker, et al., Reversal of drug resistance in a human colon cancer xenograft expressing MDR1 complementary DNA by in vivo administration of MRK-16 monoclonal antibody, J. Natl. Cancer Inst. 83:1386(1991).
M. Naito, H. Tsuge, C. Kuroko, et al., Enhancement of cellular accumulation of cyclosporine by anti-P-glycoprotein monoclonal antibody MRK-16 and synergistic modulation of multidrug resistance. J. Natl. Cancer Inst. 85:311(1993).
P.J. Fraker and J.C. Speck, Protein and cell membrane iodination with a sparingly soluble chloramide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycouril, Biochem. Biophys. Res. Commun. 80:849(1978).
J.L. Biedler, D. Casals, T-D. Chang, M.B. Meyers, B.A. Spengler, and R.A. Ross, Multidrug-resistant human neuroblastoma cells are more diffferentiated than controls and retinoic acid further induces lineage-specific differentiation, Adv. Neuroblast. Res. 3:181(1991).
J.C. Sisson, M.S. Fager, T.W. Valk, M.D. Gross, D.P. Swanson, D.M. Wieland, M.C. Tbes, and W.H. Beierwaltes, Scintigraphic localization of pheo-chromocytoma, N. Engl. J. Med. 305:12(1981).
S.D.J. Yeh, L. Helson, and R.S. Benua, Correlation between iodine-131 MIBG imaging and biological markers in advanced neuroblastoma, Clin. Nucl. Med. 13:46(1988).
S.D.J. Yeh, S.M. Larson, L. Burch, R.H. Kushner, M. Laquaglia, R.D. Finn, N.K-V. Cheung, Radioimmuno-detection of neuroblastoma with iodine-131–3F8: correlation with biology, iodine-131-metaiodobenzylguanidine and standard diagnostic modalities, J. Nucl. Med. 32:769(1991).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this chapter
Cite this chapter
Finn, R.D. et al. (1995). Radionuclides and Their Application in Oncology Research. In: Emran, A.M. (eds) Chemists’ Views of Imaging Centers. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9670-4_30
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9670-4_30
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9672-8
Online ISBN: 978-1-4757-9670-4
eBook Packages: Springer Book Archive